Drugs / BMS-986446
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06955741 | May → Sep 2025 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT06084598 | Oct 2023 → Mar 2024 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06268886 | Mar 2024 → Mar 2027 expected | early-onset autosomal dominant Alzheimer disease | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986446 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06955741 ↗ |
| Modality | Monoclonal antibody | “Anti-MTBR Tau Monoclonal Antibody” NCT06268886 ↗ |
| Route | Intravenous | “Intravenously Administered BMS-986446” NCT06084598 ↗ |